Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448
Debt
Debt-to-Equity RatioN/A
Current Ratio24.86
Quick Ratio24.86
Price-To-Earnings
Trailing P/E Ratio-11.68
Forward P/E Ratio-19.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.09 million
Price / Sales167.13
Cash FlowN/A
Price / CashN/A
Book Value$1.24 per share
Price / Book9.23
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-12,290,000.00
Net Margins-1,072.44%
Return on Equity-36.66%
Return on Assets-33.14%
Miscellaneous
Employees17
Outstanding Shares15,910,000
Market Cap$194.87 million
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.27 million. Galmed Pharmaceuticals had a negative return on equity of 36.66% and a negative net margin of 1,072.44%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
8 analysts have issued 1-year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $19.00 to $59.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $36.7778 in the next twelve months. This suggests a possible upside of 221.2% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (8/8/2018)
- 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017)
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Cara Therapeutics (CARA), NuCana (NCNA), Inflarx (IFRX), Kura Oncology (KURA), Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO) and Urogen Pharma (URGN).
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, CEO, Pres & Director (Age 53)
- Mr. Yohai Stenzler, CFO & Controller (Age 35)
- Mr. Guy Nehemya, VP of Operations (Age 33)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 51)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Media stories about GLMD stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galmed Pharmaceuticals earned a news and rumor sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.58 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Galmed Pharmaceuticals.
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vivo Capital LLC (4.98%), Nantahala Capital Management LLC (4.66%), Baker BROS. Advisors LP (4.00%), Point72 Asset Management L.P. (3.93%), Millennium Management LLC (1.98%) and First Manhattan Co. (0.82%).
Which major investors are selling Galmed Pharmaceuticals stock?
GLMD stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp.
Which major investors are buying Galmed Pharmaceuticals stock?
GLMD stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Baker BROS. Advisors LP, Point72 Asset Management L.P., Nantahala Capital Management LLC, Millennium Management LLC, First Manhattan Co., DAFNA Capital Management LLC and Unterberg Capital LLC.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $11.45.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $194.87 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
